Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.69 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.69 |
| ▸ | HTR2A | P28223 | 2/20 | 0.63 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.63 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.63 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.63 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.61 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.56 |
| ▸ | HTR1A | P08908 | 4/20 | 0.55 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.54 |
| ▸ | MPO | P05164 | 1/20 | 0.52 |
| ▸ | HTR7 | P34969 | 2/20 | 0.52 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.52 |
| ▸ | DRD2 | P14416 | 1/20 | 0.52 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.52 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.52 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.52 |
| ▸ | HTR1D | P28221 | 1/20 | 0.52 |
| ▸ | HTR1B | P28222 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31173807 | 0.91 | SLC6A4 (0.60) | HPGDCYP2C19HTR2ATRPM8MTNR1A | |
| SCHEMBL27642166 | 0.91 | SLC6A4 (0.60) | HPGDCYP2C19HTR2ATRPM8MTNR1A | |
| SCHEMBL30517178 | 0.88 | CHRNB2 (0.58) | HPGDCYP2C19HTR2ATRPM8MTNR1A | |
| SCHEMBL11949509 | 0.87 | MPO (0.70) | HPGDCYP2C19HTR2ATRPM8MTNR1A | |
| SCHEMBL1519655 | 0.84 | TSHR (0.69) | HPGDCYP2C19HTR2ATRPM8MTNR1A | |
| SCHEMBL5430044 | 0.84 | HTR2A (0.80) | HTR2ATRPM8MTNR1AMTNR1BGPR84 | |
| SCHEMBL1723364 | 0.83 | NPSR1 (0.72) | HPGDCYP2C19HTR2ASLC6A4HTR1A | |
| SCHEMBL3030323 | 0.83 | MTNR1A (0.64) | HPGDCYP2C19HTR2ATRPM8MTNR1A | |
| SCHEMBL1122353 | 0.83 | SLC6A4 (0.61) | HPGDCYP2C19HTR2ATRPM8MTNR1A | |
| SCHEMBL5432125 | 0.82 | HTR7 (0.70) | HPGDCYP2C19HTR2ATRPM8MTNR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115873020-A | RAS inhibitors | 锐新医药公司 | 2023-03-31 | — | — | CN | disclosed |
| EP-3750886-A1 | TETRAHYDROISOQUINOLINE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE THEREOF | Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CN) | 2020-12-16 | — | — | EP | disclosed |
| WO-2019183358-A2 | WHOLE CELL PROCESSES TO PRODUCE NITROAROMATICS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2019-09-26 | — | — | WO | disclosed |
| WO-2019154395-A1 | TETRAHYDROISOQUINOLINE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE THEREOF | 中国科学院上海药物研究所 | 2019-08-15 | — | — | WO | disclosed |
| WO-2018081456-A1 | HIGHLY ACTIVE SELF-SUFFICIENT NITRATION BIOCATALYSTS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2018-05-03 | — | — | WO | disclosed |
| WO-2016134145-A9 | ARTIFICIAL SELF-SUFFICIENT CYTOCHROME P450S | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2017-02-16 | — | — | WO | disclosed |
| US-20140051687-A1 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON, INC. (CA) | 2014-02-20 | — | — | US | disclosed |
| US-20140051687-A1 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON, INC. (CA) | 2014-02-20 | — | — | US | disclosed |
| US-20140051687-A1 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NEURAXON, INC. (CA) | 2014-02-20 | — | — | US | disclosed |
| US-8586620-B2 | Substituted indole compounds having NOS inhibitory activity | NEURAXON, INC. (CA) | 2013-11-19 | — | — | US | disclosed |
| US-20070072904-A1 | 1-arylsulfone-substituted indole carboxylic acids or amides; peroxisome proliferator-activated receptor PPAR modulators; obesity, diabetes, cardiovascular disorders | PLEXXIKON INC | 2007-03-29 | — | — | US | disclosed |
| US-20070072904-A1 | 1-arylsulfone-substituted indole carboxylic acids or amides; peroxisome proliferator-activated receptor PPAR modulators; obesity, diabetes, cardiovascular disorders | PLEXXIKON INC | 2007-03-29 | — | — | US | disclosed |
| WO-2007030559-A2 | 1, 3-DISUBSTITUTED INDOLE DERIVATIVES FOR USE AS PPAR MODULATORS | PLEXXIKON, INC. (US) | 2007-03-15 | — | — | WO | disclosed |
| WO-2007030559-A2 | 1, 3-DISUBSTITUTED INDOLE DERIVATIVES FOR USE AS PPAR MODULATORS | PLEXXIKON, INC. (US) | 2007-03-15 | — | — | WO | disclosed |
| US-20060258721-A1 | Substituted indole compounds having NOS inhibitory activity | NEURAXON INC. (CA) | 2006-11-16 | — | — | US | disclosed |
| CN-1845898-A | PPAR active compounds | PLEXXIKON INC (US) | 2006-10-11 | — | — | CN | disclosed |
| EP-1648867-A1 | PPAR ACTIVE COMPOUNDS | PLEXXIKON, INC. (US) | 2006-04-26 | — | — | EP | disclosed |
| US-20050288354-A1 | PPAR active compounds | PLEXXIKON, INC. | 2005-12-29 | — | — | US | disclosed |
| US-20050038246-A1 | PPAR active compounds | PLEXXIKON, INC. | 2005-02-17 | — | — | US | disclosed |
| WO-2005009958-A1 | PPAR ACTIVE COMPOUNDS | PLEXXIKON, INC. (US) | 2005-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072904-A1 | 1-arylsulfone-substituted indole carboxylic acids or amides; peroxisome proliferator-activated receptor PPAR modulators; obesity, diabetes, cardiovascular disorders | PPARG, PPARA, PPARD | HPGD 868/4885CYP2C19 435/4885HTR2A 205/4885 |
| US-20050038246-A1 | PPAR active compounds | PPARG, PPARD, PPARA | HPGD 949/4885CYP2C19 1356/4885HTR2A 1532/4885 |
| US-20050288354-A1 | PPAR active compounds | PPARG, PPARD, PPARA | HPGD 949/4885CYP2C19 1356/4885HTR2A 1532/4885 |
| US-20060258721-A1 | Substituted indole compounds having NOS inhibitory activity | NOS2, NOS1, NOS3 | HPGD 532/4885CYP2C19 301/4885HTR2A 156/4885 |
| US-20140051687-A1 | SUBSTITUTED INDOLE COMPOUNDS HAVING NOS INHIBITORY ACTIVITY | NOS2, NOS1, NOS3 | HPGD 532/4885CYP2C19 301/4885HTR2A 156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.